Registry of Patients With Hypophosphatasia

Status Enrolling by invitation

Clinical Trial Summary

In this prospective, observational, long term registry patients of all ages with a diagnosis of hypophosphatasia (HPP) are followed at participating sites in multiple countries.

Clinical Trial Description

The HPP Registry is an observational, prospective, long-term registry designed to collect data on HPP epidemiology, disease history, clinical course, symptoms and burden of disease from patients of all ages who have a diagnosis of HPP. Evaluation of safety and effectiveness data in patients with HPP who have/are receiving treatment with Asfotase alfa ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02306720
Study type	Observational [Patient Registry]
Source	Alexion Pharmaceuticals, Inc.
Contact
Status	Enrolling by invitation
Phase
Start date	April 2, 2017
Completion date	December 31, 2031

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00952484` - Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)	Phase 2
Completed	`NCT00744042` - Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)	Phase 1/Phase 2
Active, not recruiting	`NCT04181164` - Evaluation of Bone Architecture and Bone Strength in Adults With Hypophosphatasia (HPP)
Completed	`NCT02104219` - Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
Completed	`NCT01419028` - A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Completed	`NCT00739505` - Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)	Phase 1
Completed	`NCT01203826` - Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)	Phase 2